<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964298</url>
  </required_header>
  <id_info>
    <org_study_id>IC-2016-05</org_study_id>
    <nct_id>NCT03964298</nct_id>
  </id_info>
  <brief_title>Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma</brief_title>
  <acronym>imMUno</acronym>
  <official_title>Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the research is to study the activity of PD-1 inhibitors in patients with
      metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have
      already received the authorities approvals. The data collected will be crucial for the
      understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate Data collection of the efficacity of PD-1 inhibitors</measure>
    <time_frame>December 2019</time_frame>
    <description>Description of Response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival Data collection of the efficacity of PD-1 inhibitors</measure>
    <time_frame>December 2019</time_frame>
    <description>Description of PFS (Progression Free Survival)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Survival Data collection of the efficacity of PD-1 inhibitors</measure>
    <time_frame>December 2019</time_frame>
    <description>Description of Global Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability Data collection of the efficacity of PD-1 inhibitors</measure>
    <time_frame>December 2019</time_frame>
    <description>Description of Stability at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response Data collection of the efficacity of PD-1 inhibitors</measure>
    <time_frame>December 2019</time_frame>
    <description>Description of Objective response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploration of PD-1 inhibitors biomarkers</measure>
    <time_frame>December 2019</time_frame>
    <description>The study of PD-1 inhibitors biomarkers could be useful to identify a group of patients whose the molecules are most activated and then for futures studies.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Uveal Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biocollection of tumoral tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic uveal melanoma.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic uveal melanoma

          -  Patients who received at least once injection of Nivolumab or Pembrolizumab in the
             case of the disease's treatment

        Exclusion Criteria:

          -  Antecedent of another evolutionary tumor pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Manuel Rodrigues, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rodrigues</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

